Clinical Study of Combining Chemotherapy of Oxaliplatin or 5-Fluorouracil/Leucovorin with Hydroxycamptothecine for Advanced Colorectal Cancer

• Published in: Cancer biology & medicine Vol. 6; no. 2; pp. 117 - 123
• Main Authors: Sun, Yuanjue, Zhao, Hui, Guo, Yaowu, Lin, Feng, Tang, Lina, Yao, Yang
• Format: Journal Article
• Language: English
• Published: Heidelberg Tianjin Medical University Cancer Institute and Hospital 01.04.2009; Department of Medical Oncology, The Sixth People's Hospital of Shanghai Jiaotong University, Shanghai 200233, China; China Anti-Cancer Association
• Subjects: 5-fl uorouracil; colorectal cancer; hydroxycamptothecine; Medicine; Medicine & Public Health; Oncology; oxaliplatin; 上海交通大学; 临床研究; 周围神经病变; 奥沙利铂; 晚期大肠癌; 白细胞减少症; 羟基喜树碱; 联合化疗; 5-fluorouracil; hydroxycamptothecine; oxaliplatin; colorectal cancer
• ISSN: 1674-5361; 2095-3941; 1868-324X
• DOI: 10.1007/s11805-009-0117-8

OBJECTIVE To estimate effects, survival rate after the short-time efficacy, side the treatment of combining chemotherapy of oxaliplatin or 5-fluorouracil/leucovorin with hydroxycamptothecine （HCPT） for the patients with advanced colorectal cancer. METHODS From January 2002 to November 2005, 59 patients with advanced colorectal cancer confirmed by pathology were enrolled into this study in the department of medical oncology, in the Sixth People＇s Hospital of Shanghai Jiaotong University, Shanghai. Patients＇ characteristics in two groups were similarly confirmed by statistic. All 37 patients in OH group received oxalip21atin （130 mg/m^2 d1） plus hydroxycamptothecine （6 mg/m d1-4）, and all 22 patients in the HLF group received hydroxycamptothecine （6 mg/m^2 d1-4） plus leucovorin （300 mg d1-5） and 5-fluorouracil （0.375 g/m^2 d1-5）. The regimens in both groups were 21-day cycle that was repeated three weeks. The side effects were evaluated. The efficacy was estimated after two cycles of chemotherapy for each patient. RESULTS The efficacy of the treatment in the OH group with 37 patients and in the HLF group with 22 patients was estimated. The overall response rate （CR ＋ PR） was 32.4% in the OH group and 22.7% in the HLF group. There was no complete response （CR） and there was no statistical significantly difference （%2= 0.876, P = 0.704） in two groups. The 1-year survival rate was 30.98% in the OH group and 15.02% in the HLF group, and it had no significant difference between the two groups. The median PSF and OS were 5.83 months and 11.17 months in the OH group vs. 7.40 months and 10.48 months in the HLF group, and it had no significant differences between the two groups （P 〉 0.05）. The major side effects of grade III and IV in the two groups were myelosuppression and gastrointestinal reactions. The statistically significant difference in side effects appeared in leukopenia （χ^2= 17.173, P = 0.001）, nausea/vomiting （χ^2= 6.426, P = 0.039）, diarrhea （χ^2= 16.245, P = 0.000） and peripheral neuropathy. CONCLUSION The efficacy was almost equal between the OH and the HLF groups, and the two regimens can be used as the second-line treatments for the patients with colorectal cancer. Leucopenia, nausea, diarrhea and peripheral neuropathy appeared more in OH group, and anemia and thrombocytopenia were almost equal between the OH and the HLF groups.